Dublin, April 02, 2026 (GLOBE NEWSWIRE) — The “Low-Grade Glioma Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The global low-grade glioma market is experiencing a robust growth trajectory, with market size expected to increase from $1.47 billion in 2025 to $1.56 billion in 2026, representing a compound annual growth rate (CAGR) of 5.9%. Several factors have contributed to this surge, including advancements in neuroimaging technologies, improved survival rates for low-grade glioma patients, heightened awareness of brain tumor symptoms, and the expansion of oncology treatment centers.
Looking ahead, the market is set to further expand, reaching $1.94 billion by 2030 at a CAGR of 5.6%. This growth is driven by an increased emphasis on molecular tumor profiling, rising investments in targeted oncology drugs, and expanding access to specialized neuro-oncology care. Major trends anticipated in this period include early diagnosis, targeted drug therapies, multimodal treatment approaches, and personalized treatment planning.
The upward trajectory of the low-grade glioma market is closely tied to the increasing prevalence of brain tumors. Factors such as greater exposure to radiation, environmental contaminants, genetic susceptibility, and an aging population contribute to the rising incidence of these tumors. Advanced diagnostic methods and targeted therapeutic approaches, such as surgery, radiation therapy, and chemotherapy, are pivotal in managing these conditions and enhancing patient outcomes. The importance of early diagnosis and personalized care is underscored by organizations like Cancer Australia, which reported an increase in brain cancer deaths from 1,597 in 2023 to a projected 1,639 in 2025.
Notably, key players in the market are focusing on combination therapies and targeted treatments that leverage genetic alterations. Day One Biopharmaceuticals, a U.S.-based biotechnology company, launched Tovorafenib (Ojemda), a targeted therapy approved for children with unresectable or recurrent low-grade glioma associated with BRAF gene alterations. In partnership with Ipsen Biopharmaceuticals Inc., Day One aims to accelerate the global accessibility of this treatment by capitalizing on Ipsen’s oncology capabilities.
Significant players in the market include F Hoffmann La Roche Ltd, Novartis AG, AstraZeneca PLC, and others. North America was identified as the leading region in the market as of 2025, while Asia-Pacific is expected to be the fastest-growing region in the forthcoming years.
Reasons to Purchase:
- Attain a global viewpoint with this extensive report, covering 16 critical geographies.
- Analyze the effects of macro factors like geopolitical issues, trade policies, inflation, interest rates, and shifting regulations.
- Develop regional and national strategies using localized data and detailed analysis.
- Spot investment-worthy growth segments.
- Gain a competitive advantage with predictive data and insights into market drivers and trends.
- Comprehend consumer behavior through end-user analysis.
- Benchmark against major competitors focusing on market share, innovation, and brand power.
- Evaluate market potential via total addressable market and market attractiveness scoring.
- Leverage the report for both internal and external presentations with high-quality data and analysis.
- The report is routinely updated and delivered with an Excel data sheet for efficient data analysis.
- Data is accessible in an excel dashboard format.
Report Scope
Markets Covered:
- By Drug Type: Trametinib; Dabrafenib; Ivosidenib; Mirdametinib
- By Treatment: Surgery; Chemotherapy; Radiation
- By Distribution Channel: Online Pharmacies; Hospital Pharmacies; Retail Pharmacies
Subsegments:
- By Trametinib: MEK Inhibitor Monotherapy; Combination Therapy (with BRAF Inhibitors)
- By Dabrafenib: BRAF V600E-Mutant Low-Grade Glioma; Combination Therapy (with MEK Inhibitors)
- By Ivosidenib: IDH1-Mutant Low-Grade Glioma; Oral Targeted Monotherapy
- By Mirdametinib: NF1-Associated Low-Grade Glioma; MEK Inhibitor Monotherapy
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $1.56 Billion |
| Forecasted Market Value (USD) by 2030 | $1.94 Billion |
| Compound Annual Growth Rate | 5.6% |
| Regions Covered | Global |
The companies featured in this Low-Grade Glioma market report include:
- F Hoffmann La Roche Ltd
- Novartis AG
- AstraZeneca PLC
- Bristol Myers Squibb Company
- Merck & Co Inc
- Ipsen SA
- Agios Pharmaceuticals Inc
- Day One Biopharmaceuticals Inc
- Les Laboratoires Servier
- BeiGene Ltd
- Daiichi Sankyo Company Limited
- AnHeart Therapeutics Inc
- Apollomics Inc
- CStone Pharmaceuticals Co Ltd
- Avistone Biotechnology Co Ltd
- Blueprint Medicines Corporation
- Revolution Medicines Inc
- SpringWorks Therapeutics Inc
- Exelixis Inc
- Genentech Inc
For more information about this report visit https://www.researchandmarkets.com/r/zh6gav
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
